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The  molecular  basis  of  coronary  artery  disease  (CAD)  has  been  widely  studied  in  the  western  world  but
there  is  no  published  work  on  the  Malaysian  population.  This  study  looked  at the  global  gene  expres-
sion  proﬁling  of  the  peripheral  blood  of  patients  with  CAD  from  the  3 main  ethnic  groups  in  Malaysia.
Male  subjects  selected  were  based  on angiographically  conﬁrmed  CAD  (≥50%  stenosis)  and  normal  con-
trol  subjects  (0%  stenosis)  with  age  range  of  55.6  ± 5.3  and  51.0  ±  5.5  years,  respectively.  The  global  gene
expression  of 12  angiographically  documented  CAD  patients  and  11  matched  control  subjects  were per-oronary artery disease
ene expression
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alaysia
formed.  The  combined  group  samples  identiﬁed  6  up regulated  differential  expression  (DE)  genes  (GHRL,
LTA,  CBS,  HP,  ITGA2B,  and  OLR1)  and  12 down  regulated  DE  genes  (IL18R1,  ITGA2B,  IL18RAP,  HP,  OLR1,
SOD2  ITGB3,  IL1B,  MMP9,  PLA2G7,  UTS2,  and CBS)  to be  involved  in  CAD  at the  fold  change  of  1.3  with
fault  discovery  rate  (FDR)  of 1%. Three  genes,  MMP9,  IL1B,  and  SOD2  were  down  regulated  in all  the  3
ethnic  groups  making  them  potential  biomarker  candidates  for CAD  across  all three  ethnicities.  Further
veriﬁcation  in  a cohort  study  is  needed.
2  Jap©  201
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Coronary artery disease (CAD or atherosclerotic heart disease) is
 result of decades of atheroma development within the intima of
he coronary arteries [1].  The pathogenesis may  involve a complex
nteraction of many genes where each gene exerts a relatively small
ffect either alone or in combination over a period of many years
2]. Microarray gene chip technology makes it possible to study
imultaneously the expression of thousands of genes in peripheral
hole blood samples in humans [3].
Genetic research on CAD has been carried out using peripheral
lood mononuclear cells (PBMCs) rather than peripheral whole
lood. This former method requires the isolation of PBMCs using
ophisticated equipment that is not commonly available in the
linical setting. In addition to that, the PBMCs isolation tech-
ique is laborious where the blood processing requires 1–2 h of
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manipulation for RNA extraction that may  initiate interfering sig-
natures [4].  Peripheral whole blood offers an alternative option
to examine gene expression using microarray. This is because the
initiation and progression of CAD is a complex disease involving
multiple cell types and most of these cells such as monocytes, lym-
phocytes (T cells, B cells, natural killer cells), platelets, neutrophils,
eosinophils, basophils, dendritic cells, circulating stem cells, and
subsets of each of the above [5,6] are found in the peripheral whole
blood.
Although up to 80% of CAD can be attributed to major classi-
cal modiﬁable risk factors, differences seen between ethnic groups
in Malaysia [7] and Singapore [8] may  be due to genetic predis-
position. Other studies on CAD using a variety of genetic analysis
techniques such as genetic linkage, genome-wide association, and
gene expression studies have been fruitful in identifying a num-
bers of genes associated with CAD [2].  Most of these studies were
reported in western populations using cases from a predominantly
Caucasian population. There is no report on global gene proﬁling
associated with CAD in the Asian region including Malaysia. As
CAD is prevalent in Malaysia, there is a need to determine the gene
expression proﬁle of CAD in the 3 major ethnic groups namely the
Malays, Chinese, and Indians.
vier Ltd. All rights reserved.
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Since CAD is most likely a polygenic condition, approaches to
dentify potential genetic contributions to CAD have to adopt a
ene scanning technique rather than a candidate gene approach.
he availability of cost-effective new technology such as BeadChip
icroarray (Illumina, San Diego, CA, USA) [9] enables us to evalu-
te thousands of genes concurrently. This in combination with the
se of globin reduction methodology [10] can signiﬁcantly improve
ata quality and detection rate of expressed genes. This will enable
he detailed expression of genetic or molecular phenotypes of CAD
atients. From the thousands of genes expressed from cases com-
ared to controls, this study hopes to identify the genes that are
nvolved in CAD from the 3 major ethnic groups in Malaysia. The
bjectives of the study were to (1) identify genes that were dif-
erentially expressed in peripheral whole blood in CAD patients,
2) determine whether genes are differently expressed in differ-
nt ethnic groups, and (3) determine the association between gene
xpression proﬁles and CAD.
aterials and methods
tudy design
This was a cross-sectional study involving patients attending
ardiac clinics at the National Heart Institute (IJN), Kuala Lumpur,
alaysia. The research protocol was approved by the IJN Ethic Com-
ittee (RDI/02/08) in compliance with the Good Clinical Practice
uidelines. A total of 12 case subjects with a conﬁrmed diagno-
is of CAD (≥50% stenosis) regardless of the location of the lesion
ere enrolled in this study. The 12 control subjects selected were
ree from angiographically documented CAD. Controls were sub-
ects referred for angiography and were eventually shown to have
ormal coronary arteries. The subjects selected for the study had to
eet the inclusion and exclusion criteria. The inclusion criteria of
he subjects were male gender across the race of Malays, Chinese,
nd Indians between the ages of 40 and 65 years old. Meanwhile,
he exclusion criteria of the subjects were non-Malaysian, age <40
nd >65 years old with other accompanying diseases such as dia-
etes mellitus, familial hypercholesterolemia, cardiac arrhythmias,
ecent myocardial infarction/percutaneous coronary intervention
atients, post coronary artery bypass graft, unstable angina, recent
troke, renal failure (glomerular ﬁltration rate <30 mL/min), and
ncontrolled hypertension (diastolic blood pressure >100 mm Hg,
ystolic blood pressure >160 mm Hg).
ample size calculation by statistical analysis
The R package (ssize.fdr) as proposed by Orr and Liu [11] based
n the method by Liu and Hwang [12] was used to calculate the
ample size for gene expression. At the fault discovery rate (FDR)
f 5%, proportion of non-differentially expressed genes of 90%,
he desired fold change of 2 and standard deviation of 0.5, and
he desired power of 80%, the required minimum sample size is
etween 3 and 4 for each ethnicity. Therefore, in this study, 4 sam-
les were selected for the case and control of each respective ethnic
roup for Illumina Sentrix® BeadChip direct hybridization assay
i.e. total of 24).
lood sampling, RNA isolation, globin reduction and ampliﬁcation
The peripheral venous whole blood (3 mL)  was withdrawn
nto a TempusTM Blood RNA tube (Ambion, Austin, TX, USA).
mmediately after the TempusTM tube is ﬁlled up with blood,
he tube was vigorously mixed for 10 s to ensure that the sam-
le mixed well with the stabilizing solution. Genomic RNAs were
xtracted from blood using TempusTM Blood RNA kit (Ambion,
oster City, CA, USA) according to the manufacturer’s instruction.rdiology 60 (2012) 192–203 193
The extracted RNA was  subjected further to remove globin mRNA
by using the GLOBINclearTM Human Globin mRNA Removal Kit
(Ambion, Austin, TX, USA) according to the manufacturer instruc-
tions. The RNAs were then ampliﬁed using the Illumina TotalPrep
RNA ampliﬁcation kit according to the manufacturer’s instructions.
The labeled cRNA was  quantiﬁed by spectrophotometer (NanoDrop
1000, NanoDrop, Wilmington, DE, USA) and analyzed for quality by
RNA 6000 Nano Chip kits. The labeled cRNA samples were used for
the direct hybridization (according to the manufacturer’s instruc-
tions) onto the Illumina HumanHT-12 v3 Expression BeadChip.
Data analysis using bioinformatics software – Illumina
BeadStudio Gene Expression Module
The raw data obtained from the Illumina Bead Station 500
Array Reader were analyzed using Illumina GenomeStudio Gene
Expression Module. Quantile normalization of the gene expression
using GenomeStudio was performed. This bioinformatics software
enabled simpliﬁed data management for hierarchical organization
of samples, groups, groupsets, and associated project analysis. It
offers gene-level statistical analysis tools for differential analysis,
heat map  visualization, and clustering.
Data analysis using bioinformatic software – DAVID v6.7 web
based gene functional classiﬁcation and functional annotation
The results of the individual ethnic group differential expression
(DE) genes obtained from the Illumina GenomeStudio Gene Expres-
sion Module was  ﬁrst exported to Microsoft Excel to simplify the
analysis further. The analysis was to detect DE genes present only
in individual ethnic group and also DE genes present in all the 3
ethnic groups to generate the Venn diagram.
The list of DE genes identiﬁed in the Microsoft Excel was
subjected to analysis further using Database for Annotation, Visu-
alization and Integrated Discovery (DAVID) v6.7 [13,14]. This free
online web-based bioinformatics program developed by the Labo-
ratory of Immunopathogenesis and Bioinformatics (LIB, Frederick,
MD,  USA) is able to do functional interpretation of large lists of
genes derived from microarray study.
Results
Characteristics of subjects
The mean age was  51.0 ± 5.5 years in the control subjects com-
pared to 55.6 ± 5.3 years in the case subjects (Table 1). There was  no
statistically signiﬁcant difference between the ages. The mean body
mass index (BMI) was  28.0 ± 3.5 kg/m2 and 28.5 ± 3.1 kg/m2 in the
control and the case subjects, respectively (NS). There was no sta-
tistical difference in terms of systolic and diastolic blood pressure
between the control and the case subjects. The total white blood cell
(WBC) count in the controls and the cases was 7.0 ± 1.7 × 109 L−1
and 8.7 ± 1.8 × 109 L−1, respectively (p < 0.05). However, individual
WBC  count did not show any statistically signiﬁcant difference.
Both study subject groups were conﬁrmed free from diabetes
mellitus based on random and fasting glucose and HbA1c (glyco-
sylated Hb) tests. The mean total cholesterol was  4.7 ± 0.8 mmol/L
and 3.9 ± 0.9 mmol/L in the control and case subjects, respectively.
Most of the study subjects were non-smokers with only 1
smoker in the control and 2 smokers in the case groups. In the case
subjects there were 7 subjects with hypertension while there were
3 subjects in the control group. All the case subjects had stenosis in
the left anterior descending artery (LAD) while there was  no coro-
nary vessel stenosis in the control subjects. In the case subjects, 41%
had more than 2-vessel stenosis with 100% having the stenosis in
the LAD, 8.3% stenosis in left main stem artery (LMS), 16.7% stenosis
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Table  1
Demographic and baseline characteristics of the angiographically conﬁrmed normal and coronary artery disease subjects.
Control Case p-Value
Mean SD Mean SD
Characteristic
Age (years) 51.0 5.5 55.6 5.3 NS
Body  weight (kg) 75.4 10.5 77.3 10.3 NS
Height (cm) 164.0 94.3 164.7 53.5 NS
Body  mass index (kg/m2) 28.0 3.5 28.5 3.1 NS
Systolic (mm  Hg) 132.8 17.0 138.1 18.9 NS
Dystolic (mm  Hg) 83.3 8.8 85.7 9.5 NS
Active smoker 0 0
Diabetes mellitus (n) 0 0
Hypertension (n) 3 (27%) 7 (58%)
Full  blood count
WBC  count (×109/L) 7.0 1.7 8.7 1.8 <0.05
Platelets (×109/L) 255.6 38.3 238.3 50.5 NS
Neutrophils (×109/L) 55.5 7.3 54.0 10.3 NS
Lymphocytes (×109/L) 32.4 7.7 33.3 11.1 NS
Monocytes (×109/L) 6.5 3.2 8.7 3.3 NS
Eosinophils (×109/L) 5.0 2.8 4.0 1.7 NS
Basophils (×109/L) 0.9 0.9 0.5 0.5 NS
Plasma lipid levels
Total cholesterol (mmol/L) 4.7 0.8 3.9 0.9 <0.05
Triglyceride (mmol/L) 2.2 0.9 1.3 0.4 <0.05
HDL-C (mmol/L) 1.1 0.4 1.1 0.3 NS
LDL-C (mmol/L) 2.6 0.7 2.2 0.8 NS
Cholesterol/HDL ratio 4.4 1.2 3.7 1.2 NS
Level  1 100% Level 2 and 3 100% <0.01
Angiography ﬁnding on coronary stenosis
>2 vessels stenosis 0 0% 5 41.7% <0.01
LMS 0 0% 1 8.3% <0.01
LAD  0 0% 12 100% <0.01
RCA 0  0% 2 16.7% <0.01
LCX  0 0% 3 25.0% <0.01
Post-CABG 0 0% 0 0%
Medication
Antiplatelet 8 11 NS
Beta  blocker 5 3 NS
Statin 8 12 NS
ACEI  or ARB 8 10 NS
Calcium channel blocker 1 3 NS
n DL-C, 
L y arte
a
i
a
f
c
l
a
G
t
R
s
c
t
p
g
c
o
d
U
a
c, number; SD, standard deviation; NS, not signiﬁcant; WBC, white blood cell; H
MS,  left main stem artery; LAD, left anterior descending artery; RCA, right coronar
ngiotensin-converting enzyme inhibitor; ARB angiotensin receptor blocker.
n right coronary artery (RCA), and 25% stenosis in left circumﬂex
rtery (LCX) coronary artery (p < 0.01).
The control subjects were also on prescription medication
or presumed CAD before their angiogram. Both the case and
ontrol subjects were prescribed aspirin, statins, and cholesterol-
owering agents, anti-platelets, and blood-pressure lowering
gents (Table 1).
ene expression proﬁle by Illumina BeadChip microarray
echnology
The raw data of the DE genes extracted from the Illumina
eader were analyzed using Illumina GenomeStudio Gene Expres-
ion Module. The combined samples of all the 3 races with 12
ontrol and 12 case samples were analyzed with background sub-
raction and FDR by using Hochberg and Benjamini method at
-value <0.01 [15]. All the samples showed detectable genes ran-
ing from 8000 to 10,500 genes at p-value of 0.01 except Indian
ontrol subject AC81. The latter sample showed detectable genes
f only 4698 genes due to the lower mRNA reading at 75 ng/L
etected by Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA,
SA). Thus, Indian control subject AC81 was regarded as an outlier
nd has to be removed from the data analysis leaving the Indians
ontrol subject with only 3 samples. Therefore, only a total of 23high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
ry; LCX, left circumﬂex artery; Post-CABG, post coronary artery bypass graft; ACEI,
samples which consisted of 12 cases and 11 controls were selected
for further data analyses to generate DE gene.
DE gene analysis using quantile normalization and unpaired t-test
error model
The raw data samples of all the 3 races with 11 controls and 12
cases subjects were analyzed using Illumina GenomeStudio Gene
Expression Module. The analysis showed that a total of 10,124 DE
genes were identiﬁed. Out of the 10,124 DE genes, by using fold
change of 1.3, the up and down regulated DE genes was found to
be 593 and 479, respectively, with the coefﬁcient of determination
(r2) of 0.9884. Out of these genes, 26 up- (Table 2) and 53 down-
(Table 3) regulated DE genes were identiﬁed to be present across
the Malay, Chinese, and Indian groups.
Functional annotation of DE genes using DAVID v6.7
Classiﬁcation of the up regulated DE genes
From the Illumina GenomeStudio data analysis of the up reg-ulated DE genes found in the combined samples of the 3 ethnic
groups, 593 gene lists was  submitted through DAVID v6.7. Out of
a total of 593 genes, 509 genes were known and analyzed while
81 genes were unknown (Table 4). From the Functional Chart,
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Table  2
List of up regulated differential expressed genes detected in all groups as described by the Ilumina GenomeStudio module. Quantile and Cubic Spline Normalization, Hochberg
and  Benjamini method of fault discovery rate p < 0.01, Error model – unpaired t-test and Illumina custom test at Fold Change 1.3.
Up regulated genes AVG signal Fold change Deﬁnition
No. ILMN GENE Control Case
1 MYOM2  430.2 1199 2.79 Homo sapiens myomesin (M-protein) 2, 165 kDa
(MYOM2), mRNA.
2 CNTNAP2 98.8 249.5 2.53 Homo sapiens contactin associated protein-like 2
(CNTNAP2), mRNA.
3  TNFRSF17 71.3 155.2 2.18 Homo sapiens tumor necrosis factor receptor superfamily,
member 17 (TNFRSF17), mRNA.
4  LOC651751 246.9 497.2 2.01 Predicted: Homo sapiens similar to Ig kappa chain V-II
region RPMI 6410 precursor (LOC651751), mRNA.
5 MGC29506 152.3 279.8 1.84 Homo sapiens hypothetical protein MGC29506
(MGC29506), mRNA.
6  CELSR3 44.4 78.7 1.77 Homo sapiens cadherin, EGF LAG seven-pass G-type
receptor 3 (ﬂamingo homolog, Drosophila) (CELSR3),
mRNA.
7 RGL1 56.3 98 1.74 Homo sapiens ral guanine nucleotide dissociation
stimulator-like 1 (RGL1), mRNA.
8  DENND5B 55.9 92 1.65 Homo sapiens DENN/MADD domain containing 5B
(DENND5B), mRNA.
9 LOC285359 21 33.7 1.6 Homo sapiens phosducin-like 3 pseudogene (LOC285359)
on chromosome 3.
10 LOC729985 61.9 98.2 1.59 Predicted: Homo sapiens similar to CDC42-binding protein
kinase beta (LOC729985), mRNA.
11  HNRPA1L-2 522.9 829.4 1.59 Homo sapiens heterogeneous nuclear ribonucleoprotein
A1 pseudogene (HNRPA1L-2), non-coding RNA.
12  CLEC10A 39.4 61.7 1.57 Homo sapiens C-type lectin domain family 10, member A
(CLEC10A), transcript variant 1, mRNA.
13  SH3YL1 205.4 319.6 1.56 Homo sapiens SH3 domain containing, Ysc84-like 1 (S.
cerevisiae) (SH3YL1), mRNA.
14  MAPK13 192.7 299.8 1.56 Homo sapiens mitogen-activated protein kinase 13
(MAPK13), mRNA.
15 TMEM107 53.4 80.4 1.51 Homo sapiens transmembrane protein 107 (TMEM107),
transcript variant 1, mRNA.
16  DCI 52.2 78.1 1.5 Homo sapiens dodecenoyl-Coenzyme A delta isomerase
(3,2 trans-enoyl-Coenzyme A isomerase) (DCI), nuclear
gene encoding mitochondrial protein, mRNA.
17  LOC642113 1147.7 1717 1.5 Predicted: Homo sapiens similar to Ig kappa chain V-III
region HAH precursor (LOC642113), mRNA.
18 CHST12 212 317 1.5 Homo sapiens carbohydrate (chondroitin 4)
sulfotransferase 12 (CHST12), mRNA.
19  GPATCH4 35.9 53.5 1.49 Homo sapiens G patch domain containing 4 (GPATCH4),
transcript variant 2, mRNA.
20  ZDHHC1 56 81.2 1.45 Homo sapiens zinc ﬁnger, DHHC-type containing 1
(ZDHHC1), mRNA.
21  FANCE 76.4 110.3 1.44 Homo sapiens Fanconi anemia, complementation group E
(FANCE), mRNA.
22  HS.135282 45.7 64.6 1.41 Homo sapiens cDNA FLJ11554 ﬁs, clone HEMBA1003037
23  MAP3K6 112.8 158 1.4 Homo sapiens mitogen-activated protein kinase kinase
kinase 6 (MAP3K6), mRNA.
24  ABHD10 133.6 185.7 1.39 Homo sapiens abhydrolase domain containing 10
(ABHD10), mRNA.
25  RASGRP3 156.5 215 1.37 Homo sapiens RAS guanyl releasing protein 3 (calcium and
DAG-regulated) (RASGRP3), mRNA.
1.34
t
a
i
g
a
m
p
a
G
t
t
v
r
u26  CCDC43 65.7 87.9 
here were 124 records and these included 3 genes: GHRL, LGALS2,
nd LTA known to be involved in atherosclerosis and myocardial
nfarction. The functional table showed 476 records that included
enes susceptibility to obesity (GHRL). Under the Genetic Associ-
tion DB Disease Class, 3 genes were identiﬁed to be involved in
yocardial infarction. These 3 genes were ghrelin/obestatin pre-
ropeptide (GHRL), lectin galactoside-binding soluble 2 (LGALS2)
nd lymphotoxin alpha (TNF superfamily, member 1) (LTA). In the
ENERIF SUMMARY, it identiﬁed the involvement of caveolin sys-
em (CAV1, CAV3, and VEGFA)  in the endothelial cell that regulates
he vascular endothelial permeability that resulted in inﬂammatory
ascular edema leading to atherosclerosis.
Further analysis using DAVID v6.7, showed that there were 6 up
egulated DE genes that were involved in coronary artery disease
sing the combined 3 ethnic groups’ samples analysis. They were Homo sapiens coiled-coil domain containing 43 (CCDC43),
transcript variant 2, mRNA.
GHRL, LGALS2, LTA, CAV1, CAV3, and VEGFA (Table 5). In the Malays,
6 genes were found to be up regulated: GHRL, LTA, CBS,  HP,  ITGA2B,
and OLR1 (Table 6). In the Chinese only 4 genes were shown to be up
regulated: LGALS2, CAV1, CAV3, and VEGFA (Table 7). In the Indians,
2 genes were showed to be up regulated: GHRL and LGALS (Table 8).
Classiﬁcation of the down regulated DE genes
From the Illumina GenomeStudio data analysis of the down reg-
ulated DE genes, 479 gene lists were submitted through DAVID
v6.7. Out of the total of 479 genes, 423 genes were known and
previously analyzed while 56 genes were unknown (Table 9). The
Functional Annotation Clustering using classiﬁcation of high strin-
gency showing 127 clusters. The Genetic Association DB Disease
Class enlisted 29 genes that were involved in cardiovascular dis-
ease, 35 genes involved with the immune system, and 17 genes
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Table  3
List of down regulated differential expressed genes detected in all the groups as described by Ilumina GenomeStudio module. Quantile and Cubic spline normalization,
Hochberg and Benjamini method of fault discovery rate p < 0.01. Error model – unpaired t-test and Illumina custom test at Fold Change 1.3.
Down regulated genes AVG signal Fold change Deﬁnition
No. ILMN GENE Control Case
1 LTF 182.2 62 −2.94 Homo sapiens lactotransferrin (LTF), mRNA.
2  ORM1 379 131.2 −2.89 Homo sapiens orosomucoid 1 (ORM1), mRNA.
3 RUNDC3A 855.6 361.5 −2.37 Homo sapiens RUN domain containing 3A (RUNDC3A), mRNA.
4  ESPN 575.3 276.1 −2.08 Homo sapiens espin (ESPN), mRNA.
5  CASP5 200.9 101.9 −1.97 Homo sapiens caspase 5, apoptosis-related cysteine peptidase (CASP5), mRNA.
6  HIST3H2A 211.8 113.9 −1.86 Homo sapiens histone cluster 3, H2a (HIST3H2A), mRNA.
7 ANXA3 302.1 166.6 −1.81 Homo sapiens annexin A3 (ANXA3), mRNA.
8 ERAP2 1561.2 870.9 −1.79 Homo sapiens endoplasmic reticulum aminopeptidase 2 (ERAP2), mRNA.
9 LOC642684 188.9 106.4 −1.78 Predicted: Homo sapiens similar to Maltase-glucoamylase, intestinal (LOC642684), mRNA.
10  LOC642103 745 426.4 −1.75 Predicted: Homo sapiens similar to Maltase-glucoamylase, intestinal (LOC642103), mRNA.
11  SULT1B1 234.7 134.5 −1.74 Homo sapiens sulfotransferase family, cytosolic, 1B, member 1 (SULT1B1), mRNA.
12  RAB5C 248.1 147.2 −1.69 Homo sapiens RAB5C, member RAS oncogene family (RAB5C), transcript variant 1, mRNA.
13  HS.571130 90.3 53.9 −1.68 603254821F1 NIH MGC  97 Homo sapiens cDNA clone IMAGE:5297356 5, mRNA sequence
14 CXORF20 107.2 64 −1.68 Homo sapiens chromosome X open reading frame 20 (CXorf20), mRNA.
15  PLEK2 319 195.9 −1.63 Homo sapiens pleckstrin 2 (PLEK2), mRNA.
16 NSUN7 120.5 74 −1.63 Homo sapiens NOL1/NOP2/Sun domain family, member 7 (NSUN7), mRNA.
17  MICAL2 242.7 149.4 −1.62 Homo sapiens microtubule associated monoxygenase, calponin and LIM domain containing 2
(MICAL2), mRNA.
18  SLC37A3 112.2 71.2 −1.58 Homo sapiens solute carrier family 37 (glycerol-3-phosphate transporter), member 3
(SLC37A3), transcript variant 1, mRNA.
19  NR4A2 80.4 51.7 −1.56 Homo sapiens nuclear receptor subfamily 4, group A, member 2 (NR4A2), transcript variant 1,
mRNA.
20 RNASE3 245 157.6 −1.55 Homo sapiens ribonuclease, RNase A family, 3 (eosinophil cationic protein) (RNASE3), mRNA.
21  C7ORF53 181.6 117.1 −1.55 Homo sapiens chromosome 7 open reading frame 53 (C7orf53), mRNA.
22 EPB49 5024.6 3262.4 −1.54 Homo sapiens erythrocyte membrane protein band 4.9 (dematin) (EPB49), mRNA.
23  MARCH2 642.2 421.9 −1.52 Homo sapiens membrane-associated ring ﬁnger (C3HC4) 2 (MARCH2), transcript variant 2,
mRNA.
24 HS.537004 422.6 277.7 −1.52 Homo sapiens cDNA clone IMAGE:4797120
25  CR1 115.1 75.8 −1.52 Homo sapiens complement component (3b/4b) receptor 1 (Knops blood group) (CR1),
transcript variant S, mRNA.
26  SLC22A4 583.6 388.3 −1.5 Homo sapiens solute carrier family 22 (organic cation/ergothioneine transporter), member 4
(SLC22A4), mRNA.
27  GNG10 1248.9 831 −1.5 Homo sapiens guanine nucleotide binding protein (G protein), gamma 10 (GNG10), mRNA.
28  LOC643319 683.7 455.7 −1.5 Predicted: Homo sapiens similar to Transgelin-2 (LOC643319), mRNA.
29 TEK 31.6 21.2 −1.49 Homo sapiens TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous
and  mucosal) (TEK), mRNA.
30  C18ORF10 1042.3 701.3 −1.49 Homo sapiens chromosome 18 open reading frame 10 (C18orf10), mRNA.
31  TFDP2 57.4 38.7 −1.48 Homo sapiens transcription factor Dp-2 (E2F dimerization partner 2) (TFDP2), mRNA.
32  ATP7A 136.5 92.1 −1.48 Homo sapiens ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome) (ATP7A),
mRNA.
33  LOC645609 111.8 75.6 −1.48 Predicted: Homo sapiens similar to TBC1 domain family member 3 (Rab GTPase-activating
protein PRC17) (Prostate cancer gene 17 protein) (TRE17 alpha protein) (LOC645609), mRNA.
34  BST1 257.9 175.1 −1.47 Homo sapiens bone marrow stromal cell antigen 1 (BST1), mRNA.
35 ABCC13 64.2 43.6 −1.47 Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 13 (ABCC13),
transcript variant 2, mRNA.
36  LOC730820 2043.2 1401.2 −1.46 Predicted: Homo sapiens similar to nuclear receptor binding factor 2 (LOC730820), mRNA.
37  CABP5 199.3 137.4 −1.45 Homo sapiens calcium binding protein 5 (CABP5), mRNA.
38  HS.552025 321.8 221.9 −1.45 UI-E-EJ0-ahk-f-18-0-UI.r2 UI-E-EJ0 Homo sapiens cDNA clone UI-E-EJ0-ahk-f-18-0-UI 5,
mRNA sequence
39  C1ORF88 17.7 12.3 −1.44 Homo sapiens chromosome 1 open reading frame 88 (C1orf88), mRNA.
40  RBP7 532 370 −1.44 Homo sapiens retinol binding protein 7, cellular (RBP7), mRNA.
41  PYGL 2106 1471.5 −1.43 Homo sapiens phosphorylase, glycogen, liver (PYGL), mRNA.
42  MMP9 2250.7 1576.9 −1.43 Homo sapiens matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV
collagenase) (MMP9), mRNA.
43  GPN3 85.7 60.9 −1.41 Homo sapiens GPN-loop GTPase 3 (GPN3), mRNA.
44  PLAGL1 190.9 135.7 −1.41 Homo sapiens pleiomorphic adenoma gene-like 1 (PLAGL1), transcript variant 4, mRNA.
45  GRAMD1C 104.1 74.8 −1.39 Homo sapiens GRAM domain containing 1C (GRAMD1C), mRNA.
46  MANSC1 315.1 226.7 −1.39 Homo sapiens MANSC domain containing 1 (MANSC1), mRNA.
47  IL8RB 6301.7 4542.2 −1.39 Homo sapiens interleukin 8 receptor, beta (IL8RB), mRNA.
48  FLJ45337 396.2 285.7 −1.39 Homo sapiens FLJ45337 protein (FLJ45337), mRNA.
49  MAPRE3 89.8 65.4 −1.37 Homo sapiens microtubule-associated protein, RP/EB family, member 3 (MAPRE3), mRNA.
50  ABHD5 1007.5 737.3 −1.37 Homo sapiens abhydrolase domain containing 5 (ABHD5), mRNA.
51  HS.192784 57.9 42.4 −1.37 Homo sapiens cDNA FLJ36653 ﬁs, clone UTERU2001176
52 GUK1 10573 7795.9 −1.36 Homo sapiens guanylate kinase 1 (GUK1), mRNA.
apiens
pt var
i
c
s
153  PRDX5 4697.9 3477.8 −1.35 Homo s
transcrinvolved with infection. These 29 genes involved with cardiovas-
ular disease included interleukin 18 receptor 1 (IL18R1), acyl-CoA
ynthetase medium-chain family member 3 (ACSM3), interleukin
8 receptor accessory protein (IL18RAP), interleukin 1, beta (IL1B), peroxiredoxin 5 (PRDX5), nuclear gene encoding mitochondrial protein,
iant 3, mRNA.matrix metallopeptidase 9 (MMP9), arachidonate 12-lipoxygenase
(ALOX12), integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
(ITGB3), urotensin 2 (UTS2) etc. All of these genes were located at
chromosome 1, 2, 3, 6, 7, 12, 16, 17, 20, 21, and 22. The 11 genes
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Table  4
List of 81 up regulated differential expression genes of unknown functions.
No. FC SEARCH KEY ILMN GENE CHR Deﬁnition
1 2.79 ILMN 76085 HS.125087 1 AGENCOURT 7914287 NIH MGC 71 Homo sapiens cDNA clone IMAGE:6156595 5, mRNA
sequence
2  2.33 ILMN 108776 HS.545615 9 od80c09.s1 NCI CGAP Ov2 Homo sapiens cDNA clone IMAGE:1374256, mRNA sequence
3 2.01 ILMN 43180 LOC651751 Predicted: Homo sapiens similar to Ig kappa chain V-II region RPMI 6410 precursor
(LOC651751), mRNA.
4  1.95 ILMN 76756 HS.129244 20 os59g01.y5 NCI CGAP Br2 Homo sapiens cDNA clone IMAGE:1609680 5, mRNA sequence
5  1.92 ILMN 116337 HS.563486 7 UI-H-BI0-aao-g-05-0-UI.s1 NCI CGAP Sub1 Homo sapiens cDNA clone IMAGE:2710088 3,
mRNA sequence
6 1.89 ILMN 81792 HS.202475 8 Homo sapiens cDNA FLJ34356 ﬁs, clone FEBRA2012195
7  1.85 ILMN 88338 HS.373705 17 BX117372 NCI CGAP Co4 Homo sapiens cDNA clone IMAGp998E042410, mRNA sequence
8 1.79  ILMN 102747 HS.535044 Predicted: Homo sapiens similar to FLJ00290 protein (LOC441310), mRNA
9  1.79 ILMN 86874 HS.347034 10 Homo sapiens cDNA FLJ27231 ﬁs, clone SYN06240
10  1.78 ILMN 32937 LOC644979 19 Predicted: Homo sapiens hypothetical LOC644979 (LOC644979), mRNA.
11  1.70 ILMN 112234 HS.555252 9 DA371742 BRTHA2 Homo sapiens cDNA clone BRTHA2001741 5, mRNA sequence
12 1.69  ILMN 45028 LOC653352 16 Predicted: Homo sapiens similar to eukaryotic translation initiation factor 3, subunit 8,
transcript variant 4 (LOC653352), mRNA.
13  1.68 ILMN 45594 LOC649923 Predicted: Homo sapiens similar to Ig gamma-2 chain C region (LOC649923), mRNA.
14 1.66  ILMN 110505 HS.551143 9 AV727190 HTC Homo sapiens cDNA clone HTCAQG06 5, mRNA sequence
15  1.64 ILMN 91607 HS.436134 11 ta96c03.x1 NCI CGAP Lu26 Homo sapiens cDNA clone IMAGE:2051908 3, mRNA sequence
16 1.62  ILMN 84594 HS.282397 12 BX339226 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone
CS0DI069YN16 5-PRIME, mRNA sequence
17  1.61 ILMN 31058 LOC644144 17 Predicted: Homo sapiens similar to ADP-ribosylation factor 7 (LOC644144), mRNA.
18  1.60 ILMN 18612 LOC441193 7 Homo sapiens similar to zinc ﬁnger protein 469 (LOC441193), mRNA.
19  1.59 ILMN 122129 HS.569948 19 AGENCOURT 8585572 NIH MGC 113 Homo sapiens cDNA clone IMAGE:6302814 5, mRNA
sequence
20  1.59 ILMN 33006 LOC649210 Predicted: Homo sapiens similar to Ig lambda chain V region 4A precursor (LOC649210), mRNA.
21 1.57  ILMN 95224 HS.473191 Homo sapiens cDNA FLJ34428 ﬁs, clone HLUNG2000761
22  1.57 ILMN 96740 HS.495041 14 zu50f04.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:741439 5 similar to
gb:M12959 T-CELL RECEPTOR ALPHA CHAIN C REGION (HUMAN);, mRNA sequence
23 1.56 ILMN 116239 HS.563361 6 hi84g08.x1 Soares NFL T GBC S1 Homo sapiens cDNA clone IMAGE:2979038 3, mRNA
sequence
24 1.56  ILMN 38075 LOC158301 9 Predicted: Homo sapiens hypothetical protein LOC158301 (LOC158301), mRNA.
25  1.55 ILMN 81225 HS.193767 7 Homo sapiens cDNA FLJ26188 ﬁs, clone ADG04821
26 1.54 ILMN 110256 HS.550293 Homo sapiens cDNA FLJ40660 ﬁs, clone THYMU2019686
27  1.53 ILMN 30967 LOC653158 5 Predicted: Homo sapiens similar to hypothetical protein MGC40405, transcript variant 1
(LOC653158), mRNA.
28 1.52 ILMN 37967 LOC647450 Predicted: Homo sapiens similar to Ig kappa chain V-I region HK101 precursor (LOC647450),
mRNA.
29  1.50 ILMN 38142 LOC729602 18 Predicted: Homo sapiens similar to nuclear pore complex interacting protein (LOC729602),
mRNA.
30  1.50 ILMN 44140 LOC642113 Predicted: Homo sapiens similar to Ig kappa chain V-III region HAH precursor (LOC642113),
mRNA.
31  1.49 ILMN 41274 LOC650128 Predicted: Homo sapiens similar to CG1486-PA, isoform A, transcript variant 4 (LOC650128),
mRNA.
32  1.48 ILMN 34646 LOC646491 6 Predicted: Homo sapiens hypothetical protein LOC646491 (LOC646491), mRNA.
33 1.48  ILMN 77929 HS.143018 7 BX105338 Soares pregnant uterus NbHPU Homo sapiens cDNA clone IMAGp998C114347,
mRNA sequence
34  1.48 ILMN 120507 HS.568326 8 ij73g04.x1 Human insulinoma Homo sapiens cDNA clone IMAGE:5636551 3, mRNA sequence
35  1.46 ILMN 43282 FLJ32255 Predicted: Homo sapiens hypothetical protein LOC643977, transcript variant 2 (FLJ32255),
mRNA.
36  1.46 ILMN 43020 LOC642083 Predicted: Homo sapiens hypothetical protein LOC642083 (LOC642083), mRNA.
37  1.44 ILMN 124068 HS.571887 7 Homo sapiens cDNA: FLJ21429 ﬁs, clone COL04205
38  1.43 ILMN 30967 LOC728153 5 Predicted: Homo sapiens similar to FAM133B protein, transcript variant 1 (LOC728153), mRNA.
39 1.42  ILMN 114910 HS.561493 6 BX116720 Soares testis NHT Homo sapiens cDNA clone IMAGp998F241782, mRNA sequence
40  1.41 ILMN 77656 HS.135282 15 Homo sapiens cDNA FLJ11554 ﬁs, clone HEMBA1003037
41  1.41 ILMN 92566 HS.443602 6 BX093900 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGp998M23189, mRNA
sequence
42  1.41 ILMN 114974 HS.561603 in34h07.y1 Human Fetal Pancreas 1B Homo sapiens cDNA 5 similar to TR:Q14754 Q14754
ORFII, mRNA sequence
43 1.41 ILMN 41103 LOC652324 Predicted: Homo sapiens similar to anaphase promoting complex subunit 1 (LOC652324),
mRNA.
44  1.40 ILMN 73876 HS.82028 Homo sapiens mRNA; cDNA DKFZp686C10170 (from clone DKFZp686C10170)
45  1.39 ILMN 46541 LOC652685 Predicted: Homo sapiens similar to PMS1 protein homolog 2 (DNA mismatch repair protein
PMS2) (LOC652685), mRNA.
46  1.39 ILMN 34276 LOC649571 Predicted: Homo sapiens similar to Cysteine-rich protein 1 (Cysteine-rich intestinal protein)
(CRIP) (LOC649571), mRNA.
47 1.39 ILMN 37869 LOC643287 12 Predicted: Homo sapiens similar to prothymosin alpha, transcript variant 1 (LOC643287),
mRNA.
48  1.39 ILMN 75009 HS.107418 5 Homo sapiens cDNA FLJ41853 ﬁs, clone NT2RI3004161
49  1.39 ILMN 45345 LOC642859 8 Predicted: Homo sapiens similar to CG12132-PA, transcript variant 2 (LOC642859), mRNA.
50 1.38 ILMN 124127 HS.571946 1 CT000682 RZPD no.9017 Homo sapiens cDNA clone RZPDp9017N065 5, mRNA sequence
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No. FC SEARCH KEY ILMN GENE CHR Deﬁnition
51 1.38 ILMN 87278 HS.354359 19 Homo sapiens cDNA clone IMAGE:5300199
52  1.38 ILMN 44482 LOC728608 10 Predicted: Homo sapiens similar to centaurin, gamma-like family, member 1 (LOC728608),
mRNA.
53  1.38 ILMN 39027 FLJ30092 12 Predicted: Homo sapiens AF-1 speciﬁc protein phosphatase, transcript variant 3 (FLJ30092),
mRNA.
54  1.38 ILMN 37306 LOC440776 21 Predicted: Homo sapiens hypothetical LOC440776 (LOC440776), mRNA.
55  1.37 ILMN 40926 LOC653059 1 Predicted: Homo sapiens similar to K07F5.15, transcript variant 2 (LOC653059), mRNA.
56  1.37 ILMN 120922 HS.568741 10 TC125227 Human breast cancer tissue, large insert, pCMV expression library Homo sapiens
cDNA clone TC125227 5 similar to Homo sapiens LOC399828 (LOC387724), mRNA sequence
57 1.37  ILMN 21258 CDC2L2 1 Homo sapiens cell division cycle 2-like 2 (PITSLRE proteins) (CDC2L2), transcript variant 1,
mRNA. XM 001713745 XM 001713746 XM 001713747
58  1.36 ILMN 82745 HS.231861 9 Homo sapiens cDNA FLJ13474 ﬁs, clone PLACE1003593
59  1.36 ILMN 129006 HS.576825 10 DKFZp434O1935 r1 434 (synonym: htes3) Homo sapiens cDNA clone DKFZp434O1935 5,
mRNA sequence
60 1.36 ILMN 77095 HS.131087 3 BX111162 Soares testis NHT Homo sapiens cDNA clone IMAGp998E074158, mRNA sequence
61 1.35  ILMN 96725 HS.494932 14 AGENCOURT 14538823 NIH MGC  191 Homo sapiens cDNA clone IMAGE:30418790 5, mRNA
sequence
62  1.35 ILMN 132410 HS.580229 AV735490 CB Homo sapiens cDNA clone CBFBDD05 5, mRNA sequence
63 1.35  ILMN 81803 HS.202577 3 Homo sapiens cDNA FLJ34585 ﬁs, clone KIDNE2008758
64  1.35 ILMN 33917 LOC642178 Predicted: Homo sapiens similar to T-cell receptor beta chain V region 86T1 precursor
(LOC642178), mRNA.
65  1.35 ILMN 74159 HS.91389 X Homo sapiens cDNA clone IMAGE:3079901
66  1.34 ILMN 73404 HS.66187 2 Homo sapiens clone 23700 mRNA sequence
67 1.34 ILMN 109150 HS.546105 wi12b07.x1 NCI CGAP Co16 Homo sapiens cDNA clone IMAGE:2390005 3, mRNA sequence
68  1.33 ILMN 95822 HS.481464 5 Homo sapiens cDNA FLJ13116 ﬁs, clone NT2RP3002659
69 1.33 ILMN 38817 LOC643882 12 Predicted: Homo sapiens hypothetical protein LOC643882 (LOC643882), mRNA.
70  1.33 ILMN 35153 LOC644284 9 Predicted: Homo sapiens hypothetical protein LOC644284 (LOC644284), mRNA.
71  1.33 ILMN 38469 LOC643423 21 Predicted: Homo sapiens similar to T-box 1 isoform C (LOC643423), mRNA.
72  1.32 ILMN 37893 ZNF618 9 Homo sapiens zinc ﬁnger protein 618 (ZNF618), mRNA.
73  1.32 ILMN 92511 HS.443185 20 ip26b05.y1 HR85 islet Homo sapiens cDNA clone IMAGE:6218432 5, mRNA sequence
74 1.32  ILMN 79403 HS.157344 Homo sapiens mRNA; cDNA DKFZp667A182 (from clone DKFZp667A182)
75  1.32 ILMN 34855 LOC653344 15 Predicted: Homo sapiens similar to cis-Golgi matrix protein GM130, transcript variant 2
(LOC653344), mRNA.
76  1.31 ILMN 32679 LOC649095 22 Predicted: Homo sapiens hypothetical LOC649095 (LOC649095), mRNA.
77  1.31 ILMN 5744 TMEM137 Predicted: Homo sapiens transmembrane protein 137 (TMEM137), misc RNA.
78  1.31 ILMN 110820 HS.552082 4 UI-H-FH1-bﬁ-p-18-0-UI.s1 NCI CGAP FH1 Homo sapiens cDNA clone UI-H-FH1-bﬁ-p-18-0-UI
3,  mRNA sequence
79 1.30 ILMN 32935 LOC642701 18 Predicted: Homo sapiens hypothetical protein LOC642701 (LOC642701), mRNA.
80  1.30 ILMN 43635 NHEDC1 4 Homo sapiens Na+/H+ exchanger domain containing 1 (NHEDC1), transcript variant 1, mRNA.
81  1.30 ILMN 110121 HS.549989 3 Homo sapiens cDNA: FLJ22140 ﬁs, clone HEP20977
Table 5
Comparison on the average signal of up regulated differential expression genes causing coronary artery disease between the cases and controls of the combined samples of
the  3 ethnic groups.
Symbol AVG signal FC CHR Deﬁnition
Control Case
Up regulated genes
GHRL 74.8 98.2 1.3 3 Homo sapiens ghrelin/obestatin preprohormone (GHRL), mRNA.
LGALS2 136.4 202.6 1.5 22 Homo sapiens lectin, galactoside-binding, soluble, 2 (LGALS2), mRNA.
LTA  165.5 251.5 1.5 6 Homo sapiens lymphotoxin alpha (TNF superfamily, member 1) (LTA), transcript variant 2, mRNA.
CAV1 16.5 25.4 1.5 7 Homo sapiens caveolin 1, caveolae protein, 22 kDa (CAV1), mRNA.
CAV3  2.4 3.7 1.5 3 Homo sapiens caveolin 3 (CAV3), transcript variant 1, mRNA.
VEGFA 10.9 13.7 1.3 6 Homo sapiens vascular endothelial growth factor A (VEGFA), transcript variant 3, mRNA.
Table 6
Comparison of the average signal of up regulated differential expression genes causing coronary artery disease between the Malay controls and cases.
Symbol AVG signal FC
Malays control Malays case
AC121 AC421 AC70 AC36 Mean AC68 AC64 AC5 AC54 Mean
Up regulated genes
1  GHRL 60.5 24.2 74.1 94.8 63.4 224.5 111.2 78 38.5 113.1 1.78
2  LTA 143.1 140.9 194.6 136.1 153.7 363.4 200.9 664.5 257.6 371.6 2.42
3  CBS 35.2 79 101.9 153.5 92.4 55.3 94.7 113.8 209.3 118.3 1.28
4  HP 75.6 34.5 80.9 69.7 65.2 209.6 40.9 94.2 96.3 110.3 1.69
5  ITGA2B 524.7 407.7 265.9 561.4 439.9 1054.6 384.5 179.8 749.2 592.0 1.35
6 OLR1 84.8 8.4 115.5 79 71.9 283.4 22.7 104.1 51 115.3 1.60
7 CAV1 11.4 24.7 17.6 11.6 16.3 20.6 30.0 22.3 1.0 18.5 1.13
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Table  7
Comparison of the average signal of up regulated differential expression genes causing coronary artery disease between the Chinese controls and cases.
Symbol AVG signal FC
Chinese Control Chinese Case
AC391 AC34 AC50 AC51 Mean AC72 AC29 AC14 AC23 Mean
Up regulated genes
1  LGALS2 141.4 78.7 105.8 73.7 99.9 200.9 423.7 116.1 249.1 247.5 2.48
2 LTA 160.2  162.3 119.1 242.8 171.1 213.8 252.3 138.2 197.1 200.4 1.17
3 CAV1 19.2  15.4 7.2 36.5 19.6 23.3 38.7 13.8 26.3 25.5 1.30
4 CAV3  −1.4 −0.5 10.3 −0.4 2.0 1.3 2.8 2.3 6.7 3.3 1.64
5  VEGFA 6.3 12.3 13.7 11.3 10.9 32.2 12.3 10.8 5.7 15.3 1.40
Table 8
Comparing the average signal of up regulated differential expression genes causing coronary artery disease between the Indian controls and cases.
Symbol AVG signal FC
Indians control Indians case
AC62 AC58 AC3 Mean AC49 AC74 AC57 AC59 Mean
Up regulated genes
1  GHRL 42.3 101.5 67.0 70.3 112.3 99.9 75.8 82.6 92.7 1.32
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[2  LGALS2 12.8 88.0 181.9 94.2 
3  LTA 137.9 147.6 236.2 173.9 
4  UTS2 12.7 16.8 1.8 10.4 
dentiﬁed to be involved in coronary atherosclerosis were IL18R1,
TGA2B, IL18RAP, HP,  OLR1, SOD2 ITGB3,  IL1B, MMP9,  PLA2G7, and
BS located in chromosomes 2, 6, 12, 16, 17, 20, and 21. Two genes
MGP  and SPP1) were identiﬁed to cause coronary calciﬁcation. The
ther 6 genes (OLR1, SOD2 ITGB3,  IL1B, MMP9,  PLA2G7, and CBS) have
een identiﬁed as speciﬁcally causing CAD.
Following the analysis of the DE genes, there were differences in
ype and number of DE genes down regulated in the ethnic groups.
n total about 12 DE genes were identiﬁed to be down regulated in
he combined 3 ethnic groups’ analysis, they were IL18R1,  ITGA2B,
L18RAP, HP,  OLR1, SOD2 ITGB3,  IL1B, MMP9,  PLA2G7 CBS, and UTS2
Table 10).  In the Malays, only 8 genes were found to be down reg-
lated, they were LGALS2, IL1B, ITGB3,  MMP9,  PLA2G7, SOD2, UTS2,
nd CAV3 (Table 11).  In the Chinese, there were 9 down regulated
enes; CBS, HP,  IL18RAP, IL1B, ITGA2B,  ITGB3,  MMP9,  OLR1, and SOD2
Table 12). In the Indians, 7 genes (CBS, HP,  IL18R1,  IL18RAP, MMP9,
LR1 and CAV1 (Table 13)  were down regulated.
Further analysis of the DE genes showed that three genes MMP9,
L1B, and SOD2 were down regulated in all three ethnic groups.
iscussion
This study was able to identify 18 genes known to be involved
n CAD. Out of these 18 genes, 3 genes (MMP9, IL1B, and SOD2) were
onsistently down regulated across the 3 ethnic groups. The study
urther identiﬁed 137 new genes with as of yet unknown function.
any of these genes may  have signiﬁcant roles in the pathogenesis
nd progression of CAD. These genes may  modulate the effect of
AD or may  initiate the progression of CAD and further research is
eeded.
Many studies have shown the involvement of these 18 genes in
AD and most studies showed the increased expression of these
enes in the progression of CAD, in the unstable atherosclerotic
lague and in patients’ who died of myocardial infarction. Those
tudies [16–20] in particular, have shown elevated level of MMP9
ainly in patients with acute myocardial infarction (AMI), acute
oronary syndrome (ACS), and cardiac death. The MMP9  enzyme is
ssumed to participate in several stages of atherosclerosis involv-
ng leukocyte adhesion, cell migration, and matrix degradation [21].
he elevated serum MMP9  level was further shown by Fukuda et al.
22] to directly cause plaque rupture in CAD patients. However, our306.5 200.2 359.9 77.6 236.1 2.50
173.4 213.2 172.7 171.0 182.6 1.05
5.3 5.9 30.5 10.4 13.0 1.25
study demonstrated down regulation of MMP9  gene in all the 3 eth-
nic groups of CAD patients as compared to the control subjects. This
may  be because our study only recruited CAD subjects having stable
plaque without AMI  or ACS. This is supported by three large studies
involving Caucasians, Koreans, and German men on stable angio-
graphically documented CAD patients [23–25].  These investigators
failed to show any association between MMP9 enzymes with CAD
indicating a possible down regulation of MMP9 gene.
Interleukin-1 beta (IL-1) is produced by activated
macrophages as an important mediator of the inﬂammatory
response. However, in this study, IL1B gene was  down regulated in
CAD patients across the 3 ethnic groups. All the case subjects were
treated with statin while only 73% of the control subjects were on
statins. This may  be due to the fact that statin medication showed
lower IL1B gene expression. A study by Wæhre et al. [26] further
conﬁrmed that CAD patients using statins have a reduced level of
IL-1 because of the spontaneous suppression of IL-1 released
from PBMC.
Superoxide dismutase 2 is a member of the manganese super-
oxide dismutase family. This protein binds to the superoxide
by-products of oxidative phosphorylation in the mitochondria and
converts them into hydrogen peroxide and diatomic oxygen [27].
Mitochondria are an important source of reactive oxygen species
(ROS). Excess production of ROS or deﬁciency in enzymatic antiox-
idant such as SOD2 resulted in reduced production of nitric oxide
(NO) leading to endothelial dysfunction [28]. In this study there was
down regulation of the SOD2 gene which maybe consequent to the
case subject having established atherosclerosis. This is supported
by studies done by other investigators on mouse models show-
ing that mice deﬁcient in SOD2 developed atherosclerosis [29–31].
There has not been any human study to-date on the role of SOD2
and atherosclerosis.
Analyzing the 18 genes which have been reported to be related
to CAD, this study demonstrated down regulation of most of
these genes in angiographically documented CAD patients with the
exception of GHRL, LTA, CAV1, and CAV3. These genes are known to
be involved in the initiation and progression of atherosclerosis. The
control subjects were angiographically documented to be normal
but may  have early progression of atherosclerosis as shown by the
gene expression study. This has been pointed out by Libby and Ther-
oux [32] in their review of autopsy and intravascular ultrasound
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Table  9
List of 56 down regulated differential expression genes of unknown functions.
No. FC SEARCH KEY ILMN GENE CHR Deﬁnition
1 2.09 ILMN 107694 HS.544245 5 Homo sapiens clone FBA2 Cri-du-chat region mRNA
2 1.83  TUBB TUBB2A 6 Homo sapiens tubulin, beta 2A (TUBB2A), mRNA.
3 1.78  ILMN 34902 LOC642684 7 Predicted: Homo sapiens similar to Maltase-glucoamylase, intestinal (LOC642684), mRNA.
4  1.76 ILMN 44538 LOC648434 Predicted: Homo sapiens hypothetical protein LOC648434 (LOC648434), mRNA.
5  1.68 ILMN 123311 HS.571130 6 603254821F1 NIH MGC  97 Homo sapiens cDNA clone IMAGE:5297356 5, mRNA sequence
6  1.67 ILMN 168174 HLA-A29.1 Homo sapiens major histocompatibility complex class I HLA-A29.1 (HLA-A29.1), mRNA.
XM  001132736 XM 001132742 XM 001132747 XM 001132750 XM 001132753 XM 001132757
XM 001132760 XM 001132769 XM 001132772 XM 001132776 XM 001132779 XM 001132781
XM 001132783 XM 001132785 XM 001132794
7  1.64 ILMN 32589 LOC648057 Predicted: Homo sapiens similar to Guanine nucleotide-binding protein G(s), alpha subunit
(Adenylate cyclase-stimulating G alpha protein) (G-alpha-8) (LOC648057), mRNA.
8  1.61 ILMN 41055 LOC653610 1 Predicted: Homo sapiens similar to Histone H2A.o (H2A/o) (H2A.2) (H2a-615) (LOC653610),
mRNA.
9 1.59  ILMN 113570 HS.559151 10 UI-H-BI2-agq-c-12-0-UI.s1 NCI CGAP Sub4 Homo sapiens cDNA clone IMAGE:2725246 3, mRNA
sequence
10  1.59 ILMN 43540 LOC642342 9 Predicted: Homo sapiens similar to Contactin-associated protein-like 3 precursor (Cell
recognition molecule Caspr3) (LOC642342), mRNA.
11 1.58  ILMN 32441 LOC643272 3 Predicted: Homo sapiens hypothetical protein LOC643272 (LOC643272), mRNA.
12  1.55 ILMN 82256 HS.211743 11 CR978491 RZPD no.9017 Homo sapiens cDNA clone RZPDp9017I1519 5, mRNA sequence
13  1.54 ILMN 122566 HS.570385 20 DA674107 NETRP2 Homo sapiens cDNA clone NETRP2004815 5, mRNA sequence
14  1.53 ILMN 103577 HS.537907 1 UI-CF-FN0-aen-a-01-0-UI.s1 UI-CF-FN0 Homo  sapiens cDNA clone UI-CF-FN0-aen-a-01-0-UI 3,
mRNA sequence
15 1.52 ILMN 36463 LOC440731 1 Predicted: Homo sapiens hypothetical LOC440731, transcript variant 2 (LOC440731), mRNA.
16  1.51 ILMN 34849 LOC728715 12 Predicted: Homo sapiens similar to hCG38149 (LOC728715), mRNA.
17 1.50  ILMN 41137 LOC643319 8 Predicted: Homo sapiens similar to Transgelin-2 (LOC643319), mRNA.
18  1.48 ILMN 45687 LOC647041 1 Predicted: Homo sapiens hypothetical LOC647041 (LOC647041), mRNA.
19  1.48 ILMN 76935 HS.130245 1 BX110640 Soares testis NHT Homo sapiens cDNA clone IMAGp998B094156, mRNA sequence
20  1.48 ILMN 39218 LOC645609 1 Predicted: Homo sapiens similar to TBC1 domain family member 3 (Rab GTPase-activating
protein PRC17) (Prostate cancer gene 17 protein) (TRE17 alpha protein) (LOC645609), mRNA.
21 1.46  ILMN 111177 HS.552957 16 hd40e02.x1 Soares NFL T GBC S1 Homo sapiens cDNA clone IMAGE:2911994 3, mRNA sequence
22  1.45 ILMN 107615 HS.544145 5 ta60e04.x1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone IMAGE:2048478 3, mRNA
sequence
23  1.45 ILMN 105608 HS.541221 AV702854 ADB Homo sapiens cDNA clone ADBCYG05 5, mRNA sequence
24  1.45 ILMN 110801 HS.552025 20 UI-E-EJ0-ahk-f-18-0-UI.r2 UI-E-EJ0 Homo sapiens cDNA clone UI-E-EJ0-ahk-f-18-0-UI 5, mRNA
sequence
25  1.44 ILMN 42071 LOC654161 Predicted: Homo sapiens similar to AAA-ATPase TOB3, transcript variant 2 (LOC654161), mRNA.
26  1.44 ILMN 43594 LOC441019 4 Predicted: Homo sapiens hypothetical LOC441019 (LOC441019), mRNA.
27  1.43 ILMN 45950 LOC652388 Predicted: Homo sapiens similar to nodal modulator 2 isoform 2 (LOC652388), mRNA.
28 1.41  ILMN 34501 LOC653907 Predicted: Homo sapiens similar to complement receptor related protein isoform 1 (LOC653907),
mRNA.
29  1.41 ILMN 92454 HS.442696 6 603024968F1 NIH MGC 114 Homo sapiens cDNA clone IMAGE:5195560 5, mRNA sequence
30 1.41  ILMN 92557 HS.443534 4 BX117171 NCI CGAP Co3 Homo sapiens cDNA clone IMAGp998J142299, mRNA sequence
31  1.40 ILMN 33390 LOC641798 Predicted: Homo sapiens hypothetical protein LOC641797, transcript variant 1 (LOC641798),
mRNA.
32  1.40 ILMN 46692 LOC650263 Predicted: Homo sapiens hypothetical protein LOC650263 (LOC650263), mRNA.
33  1.40 ILMN 31714 LOC652755 Predicted: Homo sapiens similar to Baculoviral IAP repeat-containing protein 1 (Neuronal
apoptosis inhibitory protein) (LOC652755), mRNA.
34  1.39 ILMN 93590 HS.449276 7 BX437333 Homo sapiens THYMUS Homo sapiens cDNA clone CS0CAP006YG22 5-PRIME, mRNA
sequence
35  1.39 ILMN 27600 DDX19-DDX19L 16 Homo sapiens DDX19-DDX19L protein (DDX19-DDX19L), mRNA.
36  1.39 ILMN 114660 HS.561105 BX116726 NCI CGAP Pr28 Homo sapiens cDNA clone IMAGp998J065569, mRNA sequence
37  1.39 ILMN 32546 LOC728226 22 Predicted: Homo sapiens similar to gamma-glutamyltransferase 2, transcript variant 3
(LOC728226), mRNA.
38  1.39 ILMN 16305 FLJ45337 1 Homo sapiens FLJ45337 protein (FLJ45337), mRNA.
39  1.39 ILMN 119833 KIAA1881 Predicted: Homo sapiens KIAA1881 (KIAA1881), mRNA.
40  1.37 ILMN 105449 HS.540965 18 zp47f07.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone IMAGE:612613 3, mRNA
sequence
41  1.37 ILMN 106734 HS.543064 3 xc23f04.x1 NCI CGAP Co19 Homo sapiens cDNA clone IMAGE:2585119 3, mRNA sequence
42  1.37 ILMN 113163 HS.558286 9 AV730797 HTF Homo sapiens cDNA clone HTFAAE05 5, mRNA sequence
43  1.36 ILMN 81181 HS.192784 4 Homo sapiens cDNA FLJ36653 ﬁs, clone UTERU2001176
44  1.36 ILMN 118629 HS.566280 7f80b05.x1 Lupski dorsal root ganglion Homo sapiens cDNA clone IMAGE:3303128 3, mRNA
sequence
45  1.35 ILMN 131660 HS.579479 18 DB302602 BRAMY2 Homo sapiens cDNA clone BRAMY2033623 3, mRNA sequence
46  1.34 ILMN 85871 HS.311855 nu88b06.s1 NCI CGAP Alv1 Homo sapiens cDNA clone IMAGE:1217747, mRNA sequence
47  1.33 ILMN 121343 HS.569162 12 AV681673 GKB Homo sapiens cDNA clone GKBABD06 5, mRNA sequence
48 1.33  ILMN 36633 LOC648196 Predicted: Homo sapiens similar to BANP homolog (LOC648196), mRNA.
49  1.32 ILMN 46206 LOC648494 Predicted: Homo sapiens similar to IQ motif and WD repeats 1 isoform a (LOC648494), mRNA.
50  1.32 ILMN 32296 MGC18216 15 Predicted: Homo sapiens hypothetical protein MGC18216 (MGC18216), mRNA.
51  1.31 ILMN 110215 HS.550193 5 Human unidentiﬁed mRNA, partial sequence
52  1.31 ILMN 42983 LOC652837 Predicted: Homo sapiens similar to C-terminal binding protein 2 (LOC652837), mRNA.
53 1.31  ILMN 44594 DC36 Predicted: Homo sapiens COBW-like placental protein (DC36), mRNA.
54 1.31 ILMN 100250 HS.523076 1 DA673250 NETRP2 Homo sapiens cDNA clone NETRP2003825 5, mRNA sequence
55  1.31 ILMN 84615 HS.282800 3 AV649053 GLC Homo sapiens cDNA clone GLCBPH07 3, mRNA sequence
56 1.30  ILMN 126189 HS.574008 12 Homo sapiens unknown mRNA
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Table  10
Comparison on the average signal of down regulated differential expression genes causing coronary artery disease between the cases and controls of the combined samples
of  the 3 ethnic groups.
Symbol AVG signal FC CHR Deﬁnition
Control Case
Down regulated genes
CBS 135.5 83.4 1.6 21 Homo sapiens cystathionine-beta-synthase (CBS), mRNA.
HP  102.5 59.7 1.7 16 Homo sapiens haptoglobin (HP), mRNA.
ITGA2B 656.4 464.7 1.4 17 Homo sapiens integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen
CD41B) (ITGA2B), mRNA.
IL18R1 733.9 381.1 1.9 2 Homo sapiens interleukin 18 receptor 1 (IL18R1), mRNA.
IL18RAP 2123.2 1415 1.5 2 Homo sapiens interleukin 18 receptor accessory protein (IL18RAP), mRNA.
IL1B 1341.7  949.9 1.4 2 Homo sapiens interleukin 1, beta (IL1B), mRNA.
ITGB3 577.3 418.4 1.4 17 Homo sapiens integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) (ITGB3), mRNA.
MMP9  2250.7 1577 1.4 20 Homo sapiens matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa  type
IV collagenase) (MMP9), mRNA.
OLR1  92.2 55.4 1.7 12 Homo sapiens oxidized low density lipoprotein (lectin-like) receptor 1 (OLR1), mRNA.
PLA2G7 258.6 173.8 1.5 6 Homo sapiens phospholipase A2, group VII (platelet-activating factor acetylhydrolase,
plasma) (PLA2G7), mRNA.
SOD2 3563.7 2565 1.4 6 Homo sapiens superoxide dismutase 2, mitochondrial (SOD2), nuclear gene encoding
mitochondrial protein, transcript variant 1, mRNA.
UTS2  180.7 133.5 1.4 1 Homo sapiens urotensin 2 (UTS2), transcript variant 2, mRNA.
Table 11
Comparison of the average signal of down regulated differential expression genes causing coronary artery disease between the Malay controls and cases.
Symbol AVG signal FC
Malays control Malays case
AC121 AC421 AC70 AC36 Mean AC68 AC64 AC5 AC54 Mean
Down regulated genes
1  LGALS2 345.4 162.2 257.1 53.1 204.5 86.3 79 310.6 21.8 124.4 1.64
2 IL18R1  418.4 431.9 359.7 263 368.3 219.5 499.4 257.1 250 306.5 1.20
3  IL18RAP 1830.1 1316.9 2062.8 1193.7 1600.9 2035.9 1553.2 1010.9 1240.7 1460.2 1.10
4  IL1B 1460.8 1280.5 1191.8 1188.5 1280.4 563.8 1302.1 846.6 535.5 812.0 1.58
5  ITGB3 441.1 315.7 424.6 980.9 540.6 71.9 509.5 304.1 260 286.4 1.89
6  MMP9  2644.7 723.4 1046.4 2826.8 1810.3 2580.9 1167.2 275.9 1184.1 1302.0 1.39
7 PLA2G7 300.2 248.2 458.6 360.2 341.8 56.8 234.1 249.4 74.9 153.8 2.22
8  SOD2 3462.7 2809 3914 2587.9 3193.4 2103.4 2414.2 1555 1532.5 1901.3 1.68
9 UTS2  275.4 219.5 231.1 239.3 241.3 129.3 178.2 219.4 95.3 155.6 1.55
10  CAV3 11 −3.5 6.1 −0.3 3.3 3 −5.8 3.9 3.6 1.2 2.83
11  VEGFA 6.6 19.6 12.8 5.5 11.1 5.5 7 17.6 13.5 10.9 1.02
Table 12
Comparison of the average signal of down regulated differential expression genes causing coronary artery disease between the Chinese controls and cases.
Symbol AVG signal FC
Chinese Control Chinese Case
AC391 AC34 AC50 AC51 Mean AC72 AC29 AC14 AC23 Mean
Down regulated genes
1  GHRL 78.3 100.3 88.2 91.8 89.7 88.0 124.6 91.7 51.3 88.9 1.01
2  CBS 89.2 63.0 164.2 250.2 141.7 134.0 126.0 39.7 1.8 75.4 1.88
3  HP 154.1 61.4 113.0 94.2 105.7 59.6 71.4 −0.4 39.3 42.5 2.49
4  IL18R1 383.9 399.4 511.1 362.7 414.3 427.2 342.6 360.5 354.7 371.3 1.12
5  IL18RAP 1058.2 2216.7 1596.4 2101.9 1743.3 1026.8 876.3 1659.5 1290.5 1213.3 1.44
6  IL1B 1338.9 1229.1 1141.3 1363.3 1268.2 768.3 1010.1 486.9 1100.0 841.3 1.51
7 ITGA2B 1413.6 396.6 691.1 1544.8 1011.5 511.9 466.4 477.7 464.3 480.1 2.11
8  ITGB3 562.6 445.7 475.3 1209.6 673.3 588.4 431.3 329.7 564.2 478.4 1.41
9  MMP9 1277.2 2161.2 2280.2 1667.1 1846.4 2525.2 1365.0 582.2 932.3 1351.2 1.37
10  OLR1 261.4 161.6 59.1 20.6 125.7 27.0 66.4 15.0 14.5 30.7 4.09
218.7
501.1
247.8
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t11  PLA2G7 144.1 228.1 198.9 303.8 
12 SOD2  3508.2 2892.3 3274.7 4329.1 3
13  UTS2 288.4 332.0 246.5 124.4 
tudies. They pointed out that even portions of the coronary arterial
ree that appeared perfectly normal on angiography often harbor
 substantial burden of atherosclerosis. These ‘hidden’ lesions not
nly evade angiographic detection but also did not produce any
hysical symptoms of CAD. These challenged our traditional view
f CAD as a segmental or localized disease. As such, the classi-
cation of control subjects is subjective to the interpretation of
he researchers. Gene expression studies can help deﬁne control 142.4 247.2 150.2 289.2 207.3 1.06
 3293.0 2222.9 2329.9 1981.7 2456.9 1.43
 170.8 239.4 253.2 264.0 231.9 1.07
subjects better in the future. This hastens the need to have blood
biomarkers to help to identify the ‘hidden’ disease burden in CAD
patients rather than relying only on imaging technologies such as
angiography and magnetic resonance imaging. The use of periph-
eral blood gene expression test and not an imaging based test may
also have a more speciﬁc therapeutic implication via personalized
medication where the appropriate types of medication are given
based on the patient’s genotype.
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Table  13
Comparing the average signal of down regulated differential expression genes causing coronary artery disease between the Indian controls and cases.
Symbol AVG signal FC
Indians control Indians case
AC62 AC58 AC3 Mean AC49 AC74 AC57 AC59 Mean
Down regulated genes
1 CBS 433.5 25.9 94.3 184.6 76.6 18.6 34.4 96.5 56.5 3.27
2  HP 196.3 181.8 66.4 148.2 33.9 16.4 20.3 34.4 26.3 5.64
3 IL18R1 3861.5 715.9 365.6 1647.7 294.6 404.2 387.1 776.5 465.6 3.54
4 IL18RAP 3192.7 5718.1 1067.6 3326.1 1888.7 1755.6 957.0 1681.4 1570.7 2.12
5 IL1B  1795.1 1483.3 1285.8 1521.4 1764.1 1152.7 669.3 1200.1 1196.6 1.27
6  ITGA2B 673.8 209.7 531.0 471.5 394.4 301.0 397.4 194.9 321.9 1.46
7  ITGB3 865.4 176.8 452.2 498.1 953.8 348.8 376.8 282.2 490.4 1.02
8  MMP9 4659.6 3297.9 2173.4 3377.0 1652.7 1164.9 1774.8 3717.6 2077.5 1.63
9 OLR1 83.0 94.5 46.2 74.6 22.3 25.3 21.3 11.8 20.2 3.70
10 PLA2G7 29.5 219.8 353.2 200.8 162.6 126.5 196.3 156.4 160.5 1.25
11 SOD2 5561.2 3887.0 2974.3 4140.8 4314.6 2988.6 2036.6 4006.5 3336.6 1.24
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13  CAV3 10.7 2.8 0.7 4.7 
14 VEGFA 18.7 12.2 9.4 13.4 
This study has a few limitations. Sample size in this study
lthough small was, however, calculated a priori using the same
ethod as other studies looking at similar endpoints. Moreover,
areful matching based on the exclusion and inclusion criteria for
atient selection minimized ‘noise’ in our gene expression results.
ample size used in this study was equal to or even bigger than
ome of the studies done by other researchers [33–36] on global
ene expression proﬁling. Clearly, the aim of this study was to iden-
ify genes that can be further validated through larger studies to
onﬁrm them as biomarker candidates for CAD using peripheral
lood.
The study only examined patients with CAD of ≥50% stenosis
n angiography which can be subjected to the interpretation of
he cardiologist. In most of the previous studies, this has been the
stablished method to evaluate coronary stenosis. A more quanti-
ative evaluation of the lesion will include invasive intravascular
ltrasound method. This may, however, affect the gene expres-
ion result. By using only peripheral whole blood rather than the
therosclerotic plague itself, the study may  also limit the gene
xpression implicated in atherogenesis. Atherosclerosis is a com-
lex disease with interaction of the circulating blood and the
ndothelium, so circulating peripheral blood may  not reﬂect other
spects of the complex pathophysiology of atherogenesis. Intra-
oronary sampling may  be the more appropriate method. Being
 cross-sectional study, only a possible association between the
enotype shown and CAD can be inferred. A more meaningful eval-
ation will be a cohort study which will be more conﬁrmatory of
he role of these genes in atherogenesis.
onclusion
In conclusion, the study described the global gene expression
roﬁling by analyzing the genes being expressed in venous periph-
ral whole blood of angiographically documented CAD and control
ale subjects of the 3 main ethnic groups of Malaysia. The study
as able to identify MMP9,  IL1B, and SOD2 genes that were down
egulated. These 3 genes are potential biomarker candidates for
AD that need further veriﬁcation in a cohort study.
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